A Case of Cutaneous Squamous Cell Carcinoma Treated with Neoadjuvant Cemiplimab
Main Article Content
Keywords
immunotherapy, cemiplimab, squamous cell carcinoma, cancer
Abstract
We present a case describing the successful treatment of a 68-year-old male with high-risk cutaneous squamous cell carcinoma (cSCC) using neoadjuvant cemiplimab. The patient presented with a rapidly growing papule on the left hand, which was initially treated with wide local excision and subsequently developed axillary lymphadenopathy. After radiation therapy led to complications, the patient received four cycles of cemiplimab, resulting in significant tumor necrosis and minimal residual disease. This case underscores the potential of cemiplimab as a neoadjuvant therapy for cSCC, offering an effective treatment with fewer adverse effects compared to traditional therapies. The report highlights the importance of a multidisciplinary approach in optimizing outcomes for patients with advanced cSCC.
References
2. NCCN . Squamous cell skin cancer guidelines (Version 1.2024). Available at: https://www.nccn.org/professionals/physician_gls/pdf/squamous_blocks.pdf
3. Migden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., Lewis, K. D., Chung, C. H., Hernandez-Aya, L., Lim, A. M., Chang, A. L. S., Rabinowits, G., Thai, A. A., Dunn, L. A., Hughes, B. G. M., Khushalani, N. I., Modi, B., Schadendorf, D., Gao, B., Seebach, F., Li, S., … Fury, M. G. (2018). PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. The New England journal of medicine, 379(4), 341–351. https://doi.org/10.1056/NEJMoa1805131
4. Gross, N. D., Miller, D. M., Khushalani, N. I., Divi, V., Ruiz, E. S., Lipson, E. J., Meier, F., Su, Y. B., Swiecicki, P. L., Atlas, J., Geiger, J. L., Hauschild, A., Choe, J. H., Hughes, B. G. M., Schadendorf, D., Patel, V. A., Homsi, J., Taube, J. M., Lim, A. M., Ferrarotto, R., … Rischin, D. (2023). Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. The Lancet. Oncology, 24(11), 1196–1205. https://doi.org/10.1016/S1470-2045(23)00459-X
5. Walsh, L., Gillham, C., Dunne, M., Fraser, I., Hollywood, D., Armstrong, J., & Thirion, P. (2011). Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 98(1), 38–41. https://doi.org/10.1016/j.radonc.2010.11.009